º¦¶^¥æ´À , ¬OªÑ¥«ªº°¸µM
¶}³oÓª©¤D¦³·P©ó
Cliff¤j®¦¼w¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡zªº±M·~½×z
Åý¤p§Ìµo¨¥®É , ²`©È·\¹ï¤j®aªºµ§°O
¤]©È§j½K¤@´ò¬K¤ô , ¯}Ãa¤j®aªY½à±M·~ªº¬ü·P
©Ò¥H , ³oÓª©
¤£¥u 543 ¥i¥H½Í 1234567890abcdef ¤]Åwªï
§Æ±æ¼ö¾x¬Oì«h
¥»ª©¬O¦h¨¥°ó ¦h¤è¬Ý¨Æ ¦h±¡¹ï«Ý
¬ß±æ
¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡z¬O§Ú̪º¦@¦Pµ§°O
¡yÅý§Ṳ́@°_¬°¤ß®®¥ÍÂå¼g¤é°O¡z«h¬OÄÝ©ó¤j®aªº¦@¦P¤é°O
´Á«Ý±zªº°Ñ»P
ÁÂÁ¤j®a!
¬°¤°»ò¯«¸g¬ì§Þ±N¦¨¬°21¥@¬öªº²^ª÷¼ö¼é
¨Ó·½¡G¤õ¥Û³Ð³y ¡@2018-06-11
§@ªÌ¡GBeth Rosellini
ĶªÌ¡G»¯¦¨Às
¦ÑÄ֤ƪº§x¹Ò
¤£¥i§_»{ªº¬O¡A¯«¸g¬ì§Þ¦]¬°600¾lºØ¯«¸g¨t²Î¯e¯fªº¦s¦b¦Ó±N¦b¥þ²y½d³ò¤º¾Ö¦³¥¨¤jªº¼ç¦b¥«³õ¡CRoger Dooleyªº²Îp¼Æ¾ÚºÙ¡A¥þ²y¦³¥|¤À¤§¤@ªº¤H±w¦³»P¸£¬ÛÃöªº¯e¯f¡A¨Ã¥BÀHµÛ¦ÑÄ֤ƶiµ{ªº¥[¼@¡A³o¤@¤ñ¨ÒÁÙ±N¶i¤@¨B¤W¤É¡C¥@¬É¸gÀٽ׾¬Ʀܦôp¡A¶W¹L80·³ªº¤H¸s¤¤±N¦³¤T¤À¤§¤@·|¥Ñ©ó¦Ñ¦~è§b¯g¦Ó¥¢¯à¡A¨Ã¥B«ü¥X¥¼¨Ó¯«¸g¬ì§Þªº¬ã¨s©Mµo®i±N¬O«D±`¢¤Áªº»Ý¨D¡C
¾¨ºÞ³o¨Ç¯e¯f«D±`²±¦æ¡A¦ý¬O¥Ø«e¹ï¨äÁ{§ÉªvÀø¹ê½î¤´µM¨ã¦³¬D¾Ô©Ê¡C§Ú¹ï³o¨Ç±wªÌ¡]¥]¬A©¬ª÷´Ë¯f±wªÌ¡^ªº¬ã¨sµo²{¡A¾¨ºÞ60·³¥H¤W±w¦³¯«¸g¨t²Î¯e¯f»´«×¯gª¬ªº±wªÌ¤H¼Æ²³¦h¡A¦ý¬O¥Ñ©óªì¶EÂå¥Í¬°¥LÌÀˬdªº®É¶¡«Üµu¡A¦]¦¹¤j³¡¤À±wªÌ¤£·|±µ¨ü¥þ±ªº¯«¸gÀˬd¡C¨Æ¹ê¤W¡A¤j¦h¼Æ±wªÌ¥u¦³¦bµo¥Í¨®º×©ÎªÌ¾ÉP°©ÀYÂ_µõªº«¤j¼Y¸¨¨Æ¬G®É¤~·|³Q¶EÂ_¥X¨Ó¡C
³o¤@°ÝÃD¤]»·»·¤£¬O¶EÂ_¨º»ò²³æ¤F¡A±wªÌ¦b³Q¶EÂ_¥X¨Ó¤§«á¡A¨äªvÀø©MÂà¶E¹Lµ{¤]·|¥Rº¡¥¢»~©M»Ùê¡C¥Ø«e¤w¦³ªºÃĪ«±a¦³¤@¨t¦Cªº°Æ§@¥Î¡A¹ï±wªÌªº¥Í¬¡½è¶q·|³y¦¨«¤j¼vÅT¡C¨Ò¦p¡A§Úªº¬ã¨sµo²{¤j¦h¼Æ65·³¥H¤Wªº±wªÌ¨C¤Ñ»ÝnªA¥Î¤CºØÃĪ«¡C
³o¨Çµo²{¥i´d¦aªí©ú¡A¥Ñ©ó¶EÂ_ªº©µ»~¡B¥i¿ï¾ÜªvÀø¤â¬qªº¯Ê¥F©M¥O¤H¤£§ÖªºÃĪ«ªvÀø¡A§Ú̥ثe¹ï¯«¸g¯e¯fªººÞ²zÄY«¤£¨¬¡CµM¦Ó¡A¬ã¨sµ²ªG¤]«ü¥X¡A¯«¸g¬ì§Þ¥«³õªºµo®i¤w¸g¦¨¼ô¡A¨Ã¬°¸Ñ¨M¥Ø«e§Ú̪ºªÀ·|©Ò±Á{ªº¤@¨Ç«¤j°·±d°ÝÃD´£¨Ñ¤F¼ç¤O¡C
ÀHµÛ¹ï¸Ñ¨M¤è®×ªº»Ý¨D¤£Â_¼W¥[¥H¤Î¤£Â_¨ú±oªº¶i®i¡A¯«¸g¬ì§Þ²©R±N·|¦³§ó¦hªº¸êª÷©M·P¿³½ìªÌ´é¤J¡C¦]¦¹¡A»¡¯«¸g¬ì§Þ±N¦¨¬°21¥@¬öªº²^ª÷¼ö²@¤£¬°¹L¡C
¤ß®®¦¨¥\¡A¤ß¶V´r§Ö
¼ÐÃD§ï¬°¡G
¥@¬É¶V§Ö ¤ß¶VºC?
¤º®e§ó¬°¡G
YSNG-12¦¨¥\ ,±N¥i¥H¦¨¬°¥þ¥@¬É²Ä¤@´Ú¤fªAªº¦Û±þ¨¾ªvÃĪ« ,±N¬O¯uªº±Ï¤H¤@©Rªº·sÃÄ
ÁÂÁ¤j®a¡I
liaw6575¤j¤j¹ï¦Û±þªº²Îp¸ê®Æ¤À¨É
¥@¬É¶V§Ö ¤ß®®ºC?
liawbf.pixnet.net/blog/post/47974122
¦P¬O¥LÁ|¥xÆW¦Û±þ¨¾ªv¾Ç·|2015ªº¾ã²z¸ê®Æ
¥þ²y¤H¤f¤¤¬ù¦³ 9% ªº¤H¤@¥Í¤¤¦Ü¤Ö¥X²{¤@¦¸¦Û±þ·N©À
¤@Ó¸ó¶V17°ê½Õ¬d84850¤Hªº¶W¤j³W¼Ò¬ã¨s
µo²{¦UÃþ«¬²×¥Í²±¦æ²v,¥]¬A¦Û±þ·N©À 9.2% ,¦Û±þpµe 3.1% ,¦Û±þ¥ø¹Ï 2.7% ...
¦AªÌ
¦³¦Û±þ·N©ÀªÌªº25%¤ñ¨Ò ,·|²£¥Í¦Û±þ¥ø¹Ï;¦Û±þ·N©ÀªÌªº5%¤ñ¨Ò ,·|¦Û±þ§¹¦¨
¦]¦¹ ,¨¾ªv¦Û±þ·N©À ,´N¬O¦b¹w¨¾¦Û±þ
liaw6575¤j¤jµ²½×¹D
YSNG-12¦¨¥\ ,±N¥i¥H¦¨¬°¥þ¥@¬É²Ä¤@´Ú¦Û±þ¨¾ªvÃĪ« ,±N¬O¯uªº±Ï¤H¤@©Rªº·sÃÄ
ÁÂÁÂliaw6575¤j¤jªº¤À¨É
¬Ý¬Ý¦bÆ{§í¯g»â°ìªºBTD , ¾AÀ³¯g¦U¦³¤£¦P
esketamine : ( ÀR¯ß ? ©Î »ó¤ºµ¹ÃÄ )
2013/11
for treatment-resistant depression
2016/08
The designation was granted for major depressive disorder with imminent risk for suicide.(ÄY«§íÆ{¯g¨Ã¦³§Y±Nµo¥Íªº¦Û±þ·ÀI)
Rapastinel : ( NMDA receptor partial agonist ) ÀR¯ßµ¹ÃÄ
2016/01
for Adjunctive Treatment of Major Depressive Disorder (MDD)
SAGE-547 : ( GABA modulator ) ÀR¯ßµ¹ÃÄ
2016/09
ªvÀø²£«á§íÆ{¯g¡]PPD¡^
SAGE-217 : ( GABA modulator ) ¤fªA
2018/02
for the treatment of major depressive disorder (MDD)
©Ò¥H SNG-12 nÂ\¦bþ¸Ì©O?
³o¼Ë¦n¶Ü?
for major depressive disorder with suicidal ideation ?
²¦³º¶W¹L940¸Uªº¬ü°ê¤H¦³ÄY«ªº¦Û±þ«äºû , À³¸Ó¦³¥«³õ¤~¹ï
J«ä¶Ã·Q¤§Á|
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
¬ü°ê¦Û±þ¼éªº¿³°_¥YÅã¤F·s«¬§íÆ{¯gÃĪ«ªº»Ý¨D
2018¦~6¤ë9¤é/ 4:30 AM / 8¤p®É«e§ó·s
Julie Steenhuysen
ªÛ¥[ô¡]¸ô³zªÀ¡^ - ¬ü°ê¦Û±þ²v¤j´T¤W¤É¡A¥O¤H·NÃѨì»Ýn§ó¦³®Ä¦aªvÀø««×§íÆ{¯g¡A¬ã¨s¤HûºÙ³o¬O¤@ӴƤ⪺µo®i»â°ì¡A¤j³¡¤À»sÃĤ½¥q¤w¸g©ñ±ó¤F³o¤@»â°ì¡C
¬ü°ê½Ã¥Í·í§½¶g¥|ªí¥Ü¡A¦Û¥»¥@¬öªì¥H¨Ó¡A¥þ°ê¦U¦aªº¦Û±þ²v«æ¼@¤W¤É¡A¨Ã©IÆ~±Ä¨úºî¦X±¹¬I¸Ñ¨M§íÆ{¯g°ÝÃD¡C¸Ó³ø§i¦b¦P¤@©Pµo¥¬¡A§@¬°¦W¤H Anthony Bourdain ©M Kate Spade ªº°ª½Õ¦Û±þ¡C
¸ô³zªÀµLªk½T©wBourdain©ÎSpade¬O§_¥¿¦b±µ¨üÃĪ«ªvÀø¡C
®Ú¾Ú¬ü°êÃÄ«~¬ã¨s»P»s³y°Ó¨ó·|ªº³ø§i¡A»sÃĤ½¥q¥¿¦b¶}µo°w¹ïºë¯«°·±d°ÝÃDªº140ºØÀøªk¡A¨ä¤¤39ºØ°w¹ï§íÆ{¯g¡C³o»P¸Ó¦æ·~¦b1100ºØ¹êÅç©ÊÀù¯gÃĪ«¤è±ªº¤u§@¬Û¤ñ¡A³o¨ÇÃĪ«¥i¥H±±¨î¤@¨Ç³Ì°ªªº»ù®æ¡C
...
¨ä¤¤¤å¤º´£°_ªº´XÀÉÁ{§É¤¤ÃĪ« , ³£¬O§Ú̦ռô¯à¸ÔÀò±oBTDºa»Îªº·sÃÄ
J&J¡¦s esketamine
SAGE ªº SAGE-547 , 217
Allergan Plc ªº rapastinel ( GLYX-13 )
¦Ñ¥v¤j¤j
liaw6575¤j¤j
ÁÙ¦³´²¥¬¦b¥²´Iºôªº¨ä¥L¤j¤j¤å³¹
³£¦³±´°Q
¥i±¤¦Ñ¥v¤j¤jªººô¶ ¤p§Ì¥´¤£¶}
liaw6575¤j¤j ½Ð°Ñ
liawbf.pixnet.net/blog/category/2056471
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
µM¦Ó¦³³oºØ¦Û±þ·N©Àªº±wªÌ¦h¤£¦h©O¡H
®Ú¾Ú .mentalhealth.gov ºô¯¸ªº¸ê®Æ
On average, 122 Americans die by suicide each day. Suicide is the second leading cause of death among 15-24 year olds and more than 9.4 million adults in the United States had serious thoughts of suicide within the past 12 months.
¦b¬ü°ê¡A¹L¥h12Ó¤ë 940 ¸U¤H¦³ÄY«ªº¦Û±þ«äºû
¯u¬O¶W¥G¤pªº·Q¹³
ì¨Ó¦³³o»ò¦h¤H³B¦bÄY«¦Û±þ«äºûªº±¡¹Ò¤¤
Ä@Ãļt¬ãµo·sÃÄ¥H¸Ñ²³¦h±wªÌªºµhW©M»Ý¨D
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a¡I
¨Ó·½¡GÃÄ©ú±d¼w¡@2018-06-07
med.sina.com/article_detail_100_2_47080.html
¤µ¤é¡A Axovant Sciences «Å¥¬¤w±qOxford BioMedica Àò±o¥þ²y¿W®a±ÂÅv¡A¶}µo¨Ã±À¼s©¬ª÷´Ë¯f°ò¦]ÀøªkAXO-Lenti-PD ¡]´¿¥Î¦WOXB-102 ¡^¡CAxovant ¹wp±N©ó¤µ¦~©³¶}©l¹ï±ß´Á©¬ª÷´Ë¯f±wªÌ¶i¦æAXO-Lenti-PD ªº1/2 ´Á¾¯¶q»¼¼W¬ã¨s¡C
AXO-Lenti-PD §@¬°¤U¤@¥N°ò¦]Àøªk¡A¬°©¬ª÷´Ë¯fªºªvÀø±a¨Ó·sªº¥i¯à¡COxford BioMedica ¤w¸g¦¨¥\§¹¦¨ProSavin® ªº1/2 ´Á¬ã¨s¡A¨Ã©è¹F¥Dn²×ÂI¡C¨äµ²ªGªí©ú¡A¦b6 Ó¤ë©M12 Ó¤ë®É¡A³q¹LUPDRS ²ÄIII ³¡¤Àµû¤À´ú¶q¡A¸ÓÃĪ«ÃÒ©ú¤F¨ä¦w¥þ©Ê©M@¨ü©Ê¡A¥H¤Î¹ï¹B°Ê¥\¯àªºÅãµÛ§ïµ½¡CÁöµM©¬ª÷´Ë¯f·|¾ÉP³vº¥°h¤Æ¡A¦ý¸ÓÃĪ«µ¹¤j¦h¼Æ±wªÌ±a¨Óªº§ïµ½¥i«ùÄò¹F¥|¦~¡C
®Ú¾Ú»P Oxford BioMedica ñqªº³\¥i¨óij±ø´Ú¡AAxovant ±Nº¥ý¤ä¥I 3000 ¸U¬ü¤¸¡A¥HÀò±oAXO-Lenti-PD ¤Î¨ä«e¨²£«~ProSavin® ªºÅv§Q¡C
¦pªG¸ÓÃĪ«Àò±o§åã¡AOxford BioMedica ÁÙ¦³¸ê®æÃB¥~Àò±o¶W¹L 8.12 »õ¬ü¤¸ªº¶}µo¡BºÊºÞ©M±À¼s¨½µ{¸O¶O¥Î¡A¥H¤ÎAXO-Lenti-PD ªº²b¾P°âÃB¯S³\Åv¨Ï¥Î¶O¡C
2018-06-07 11:55¤¤¥¡ªÀ «n§ë7¤é¹q
udn.com/news/story/7266/3185057?from=udn_ch1cate6649_pulldownmenu
³¯«í¥Íªí¥Ü¡A«äı¥¢½Õ¯gªº²±¦æ²v¬ù¬°3/1000¡A¦pªG¤Î¦µo²{¡A¤Î¦ªvÀø¡A¥ÎÃÄ´_쪺ª¬ªp·|§ó¦n¡A¦P®É¨¾¤î¸£³¡·l¶Ë¡A¥un¦bµo¯f¤@¦~¤º´NÂå¡A¤j¬ù¥i¥H«ì´_7¦¨¥H¤Wªº¸£³¡¥\¯à¡A¤£¹L¥ÎÃĤ£¯à¶¡Â_¡A¦]¬°´¿¦³¬ã¨s«ü¥X¡A§Y¨Ï¤¤Â_¥ÎÃĮɶ¡¤£¨ì10¤Ñ¡A¯gª¬´_µo¥B»Ýn¦í°|ªº·ÀI«o°ª¹F2¿¥H¤W¡C
³¯«í¥Í»¡¡A«äı¥¢½Õ¯g¦pªG¤£¿n·¥ªvÀø¡A·|´c¤Æ¨ìµLªk¦Û§Ú·ÓÅUªºµ{«×¡A¯fÃÑ·P¤]·|ÀHµÛ¯e¯f´c¤Æ¦Ó®ø¥¢¡A¯f±w¦bµo¯fªì´ÁÁÙª¾¹D¦Û¤v»P¥¿±`¤H¦³ÂI¤£¤@¼Ë¡A¤£¹LÀHµÛ¯fµoÀW²vªº¼W¥[¡A¯f±w·|¶}©l¥D°Ê¸ÑÄÀ¦Û¤vªº·P¨ü¦Ó³vº¥§Î¦¨©TµÛªº·Qªk¡A¦P®É³vº¥¥¢¥h¯fÃÑ·P¡C
³¯«í¥Íªí¥Ü¡A¯f±w¦pªG¤Î¦¥B¿n·¥ªvÀø¡A³Ì¦nªºª¬ªp¤´µM¯à°÷©M¥¿±`¤H¤@¼Ëªº¥Í¬¡¡Aºû«ù쥻ªºªÀ·|¾·~¥\¯à¡A¤£¹L«äı¥¢½Õ¯g¤£ºÞ¹ï¯f±w¡B®a¤H¥H¤ÎªÀ·|¨Ó»¡³£¬Oªø´Á§Ü¾Ô¡A°ß¦³¦U¤è±«O«ù¦X§@¡A¤~¯à¹F¨ì³Ì¦nªºªvÀø®ÄªG¡C
2018-06-05
news.ltn.com.tw/news/focus/paper/1206423
.¥h¦~27¸U¤H¥¢´¼ ²±¦æ²v¬ù8¢H
.¥¼¨Ó45¦~ ®£¤é¼W36¦W¥¢´¼±wªÌ
.¶W¹L5¦¨±wªÌ ¥Ñ®a¤Hªø´Á·ÓÅU
·ÓÅ@°ÝÃD³ô¼~¡I¥¼¨Ó45¦~®£¤é¼W36¦W¥¢´¼±wªÌ
2018-06-05 07:32
news.ltn.com.tw/news/life/breakingnews/2447805
¨Ó·½¡G°·ÂI¤lihealth¡@2018-06-04
med.sina.com/article_detail_100_2_46867.html
ù¤ó¡]Roche¡^¥¿¦¡«Å¥¬¡A²×¤î3¦~«e§ë¸ê1.2»õ¬ü¤¸±qTrophos¤½¥q¦¬ÁʪºolesoximeªvÀøSMA2«¬ªºÁ{§É¸ÕÅç¡C
SMA¬O¤@ºØÄY«ªº¯«¸g¦Ù¦×¯e¯f¡A¯gª¬¬O¹B°Ê¯«¸g¤¸ªº³à¥¢¡A¾ÉP¶i¦æ©Ê¦ÙµL¤O©MÅõºÈ¡C
»P¦¹¦P®É¡A·s¿³ªº°ò¦]ªvÀø¤è¿³¥¼¦ã¡CAveXis¤½¥qªº¥D¥´²£«~AVXS-101¡A §Q¥Î¸¢¬ÛÃö¯f¬r¸üÅé¡]AAV¡^§Þ³N¡A±NSMN1°ò¦]ª½±µ¹B°e¨ìÅ餺¡A´Á±æ¯à®Ú¥»ªvÀø¯áÅè©Ê¦ÙµäÁY¡C
¦b¦UÓÃþ«¬ªºSMA¤¤¡A³ÌÄY«§Î¦¡¬O1«¬SMA¡C1«¬SMA¥Ñ©ó¹B°Ê¯«¸g¤¸³à¥¢©M¬ÛÃö¦Ù¦×°h¤Æ¡A¤j³¡¤À±wªÌ¦b¨â·³«e´N»Ýn¥Ã¤[©Ê©I§l¤ä«ù¡C
AveXis¤½¥q¥Ø«e¶i¦æSVXS-101ªº¤T´ÁÁ{§É¸ÕÅç¡AªvÀøSMA1«¬±wªÌ¡C
4¤ë¡A¥t¤@®a·ç¤hÃÄ¥ø¿ÕµØ¤@»ïÅå¤H¡A¥H87»õ¬ü¤¸ªº»ù®æ¦¬ÁʤFAveXis¤½¥q¡C¿ÕµØªº¤J§½¡A§ó¥[¥[¼@¤FSMAªvÀø»â°ìªºª§¹Ü¡C
*********************************************************
JBC¡Gºñ¯ù¤¤ªº¯S®í¤À¤l©Î¯à¦³®Ä§í¨î¤ßŦ¯fµo§@©M¤¤·µo¥Í
¨Ó·½¡G ¥Íª«¨¦ ¡@2018-06-04
med.sina.com/article_detail_103_1_46856.html
ªñ¤é¡A¤@¶µ¥Zµn¦b°ê»ÚÂø»xJournal of Biological Chemistry¤Wªº¬ã¨s³ø§i¤¤¡A¨Ó¦ÛÄõ¶}´µ¯S¤j¾Ç©M§Q¯÷¤j¾Çªº¬ì¾Ç®a̳q¹L¬ã¨sµo²{¡Aºñ¯ù©Î¯à¦³®Ä§í¨î¦]°Ê¯ßµ°¼Ëµw¤Æ¤Þµoªº¤ßŦ¯fµo§@©M¤¤·±wªÌªº¦º¤`¡C
¤å³¹¤¤¬ã¨sªÌªí¥Ü¡A¤@ºØ¦s¦b©óºñ¯ù¤¤ªº¯S®í¤Æ¦Xª«¤£¶È¯à°÷°§Cªüº¸¯÷®üÀq¯f±wªÌ¤j¸£¤¤ªº¾ý¯»¼Ë´³¶ô¥~¡AÁÙ¯à°÷¯}¸H¨Ã¥B¤À¸Ñ¦åºÞ¤¤¼ç¦b¦MÀIªº³J¥Õ½è´³¶ô¡C°Ê¯ßµ°¼Ëµw¤Æ±wªÌ°Ê¯ß¤¤·|¦s¦b¯×ªÕª«½èªº¿n²Ö¡A¨ä·|°§C±wªÌ¤j¸£©M¤ßŦªº¦å¬y¶q¡A¦b¯e¯fªº±ß´Á¶¥¬q¡A¦W¬°¸ü¯×³J¥ÕA-1¡]apoA-1¡^ªº³J¥Õ½è´N·|§Î¦¨¾ý¯»¼Ë³J¥Õ¨I¿nª«¡A¨äÃþ¦ü©óªüº¸¯÷®üÀq¯f±wªÌ¤j¸£¤¤ªº¨I¿nª«¡A³o¨Ç¨I¿nª«¯à¦b°Ê¯ßµ°¼Ëµw¤Æ´³¶ô¤¤°ï¿n¡A¨ä·|¤£Â_¼W¥[´³¶ôªº¤Ø¤o¡A¶i¤@¨B°§C±wªÌ°Ê¯ß¤¤ªº¦å¬y¶q¡A¦Ó¥B·|¨Ï±o´³¶ô«D±`¤£Ã©w¡A±q¦Ó¼W¥[±wªÌ¤ßż¯fµo§@©M¤¤·ªº·ÀI¡C
¬ã¨s¤Hûµo²{¡Aºñ¯ù¤¤³Ì±`¨£ªº¦¨¤À¡X¨à¯ù¯À¡]ªí¨S¹¤l¨à¯ù¯À¨S¹¤l»Äà¡AEGCG¡^©Î³\´N¯àµ²¦XapoA-1¾ý¯»¼Ë³J¥ÕÅÖºû¡A±q¦Ó´N¯à±N³oºØ¾ý¯»¼Ë³J¥ÕÂà¤Æ¦¨¬°¤£¤Ó·|¹ï¦åºÞ³y¦¨·l¶Ëªº¤p«¬¥i·»©Ê¤À¤l¡C
Tannic acid ©M EGCG ³£¦³¦@¦Pªº°ò¥»³æ¦ì---¨S¹¤l»Ä
¤£ª¾¬O§_¤]¦³Ãþ¦ü¥\¯à ?
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
liawbf.pixnet.net/blog/post/47963937
.³zµøºë¯«¤Àµõ¯g
.¯d¦í³Ì«á¤@¤ù°O¾Ð¡V²Ó»¡ªü¯÷®üÀq¯g
.¯à¹w¨¾¶Ü¡Hªü¯÷®üÀq¯g
ÁÂÁÂliaw6575¤j¤j¤Þ¤¶
ÁÂÁ¤j®a!
·PÁ´£¨Ñ³Ìªñ¤½¥q¬ÛÃö°T®§...§Ú¨Ó¸É¥R¤@Ó©M§Aªº¤G¤T¨Æ¥i¯à¦³Ãöªº...
¥»¦¸¿W¥ß¸³¨ÆÔ¿ï¤H¦W³æ...³\¥ü¼yªk¾Ç³Õ¤h...
°õ·~¸g¾ú:
¦b°ê¤º¤Î¸ó°ê°Ó °È»Pª§ºÝ³B²z¡B«H°Uªk¡B¸ê²£³W¹º¡BÃÒ¨é¥æ©öªk¡B
´¼¼z°]²£Åvªk¤Î¤£°Ê²£ªkµ¥»â°ì¦³Â×´I¸gÅç¡A¨Ã¦b¤j¾Çªk«ß¨t¾á¥ô¬ÛÃö±Ð¾¡C
³\«ß®v´¿¾á¥ô¦a¤èªk°|ªk©x¶W¹L¤Q¦~
¥Dn±M·~»â°ì:
«H°Uªk¡B¸ê²£³W¹º¡BÃÒ¨é¥æ©öªk¡Bª§ºÝ³B²z¡B´¼¼z°]²£Åvªk
¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ~~
Uspto Issues Trademark: Syneurx
www.highbeam.com/doc/1P4-2020372070.html
The trademark SYNEURX (Reg. No. 5419038) was issued on March 6 by the USPTO.
*****************************
SyneuRx Neuroscience HK Limited (CR No. 2684857)
www.hkcompanycheck.com/syneurx-neuroscience-hk-limited-clxcfee/
SyneuRx Neuroscience HK Limited was incorporated on 23 Apr 2018 as a Private company limited by shares registered in Hong Kong.
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
2018-06-03 14:25Áp¦X³ø °OªÌ½²®e³ì¢¬§Y®É³ø¾É
udn.com/news/story/7266/3177414?from=udn_ch1cate6649_pulldownmenu
½ÃºÖ³¡²Îpµo²{¡AK¥L©R¤´¬O¦M®`¦~»´¥@¥N³ÌÄY«ªº¬r«~¡C°ª¥«Áp¦XÂå°|ªc§¿¬ì¥DªvÂå®v½²¨q¨k2003¦~±qÁ{§É®×¨Òµo²{¡A§l¹K¥L©R·|¾ÉP»H¯ÖÅÖºû¤Æ¯fÅÜ¡A°ê¥~ª½¨ì2007¦~¤~¦³¬ÛÃö®×¨Òµoªí¡F§Y«K¦h¦~¨Óªc§¿¬ìÂå®v¤£Â_¦V¯f±w«Å¾É¡A¥L·P¹Ä¡u15¦~¨Ó¯f±w¤¤10Ó¦³8Ó§Ù¤£±¼¡I¡v
½²¨q¨kªí¥Ü¡A15¦~«e¤@¦W24·³¤k«Ä¦]ÀW§¿¡B¦å§¿¨D¶E¡A¦Ûz¤@¤Ñn¤W20¦¸´Z©Ò¡Aµh¤£±ý¥Í¡FX¥úÀˬdµo²{¤k«Ä»H¯ÖÅËÁY¡B»H¯Ö¾ÀÅÜ«p¡A§ó±q»H¯ÖÃè¤W¬Ý¨ì»H¯Ö¾À¼ìÄê¡B¥X¦å¡A¥u¯à¥Î¡uºG¤£§Ô¸@¡v§Î®e¡C
½²¨q¨k»¡¡A¨º°}¤l¦]±Æ§¿»Ùê¨D¶Eªº¦~»´±wªÌÅܦh¡AÅý¥L¦Ê«ä¤£±o¨ä¸Ñ¡Aª½¨ìÅ@²z®v¦b¤@¦Wªì¶E±wªÌ¯f¾ú¤W¼gµÛ¡u¤w©ÔK¤@¦~¡v¡A¥L«éµM¤j®©¡AÀH«á°w¹ï³o¸s±wªÌ®i¶}¤@¨t¦C§¿²G¡B¦å²G¤Î¬r¤Æª«Àˬd¡A½T»{¬OK¥L©R¤¤ªº¤Æ¾Çª«½è¹ï»H¯Ö³y¦¨¶Ë®`¡A¤w¦b2004¦~¥¿¦¡µoªí¬ã¨sµ²ªG¡C
15¦~¨Ó¡A§l¹K¥L©Rªº¦~»´¤H¤f¦³¼WµL´î¡A½²¨q¨k·P´nªí¥Ü¡A©ú©ú8¡B9¦¨±wªÌ¥i³z¹LÃĪ«Àò±o«Ü¦nªºªvÀø®ÄªG¡A¦ý¦³8¦¨±wªÌ¦b¯gª¬§ïµ½«á«ùÄò§l¹K¥L©R¡A¦~¬ö»´»´´N¨â°¼µÇ¤ô¸~¡B¬Æ¦Ü±o¤Á°£»H¯Ö¡C¥L»¡¡A³Ì¦¦¬ªvªº10Ó±wªÌ¤¤¡A¥u¦³2¤H¦¨¥\§Ù±¼¡A¡u¤@Ó¬O¦]¤JºÊªA¦D¡A¤@Ó«h¬O³Q°e¥X°ê¥´¤u«×°²¡I¡v
Ó¤H·Qªk
Ӫѱq°ª»ù230¦V¤U¦ôºâ³Ñ¤U2¦¨§C»ù¦b46¤¸¤Ï¼u¨ì¤µ80¥H¤W...¥«³õ«Ü¦h¬ÛÃöӪѬO¦p¦¹ÅܤÛ
¤½¥q§V¤O¤£ÅÜ®ø®§°t¦X¥X²{ªÑ»ù¤´Äò¤W¦æ....§Æ±æ¤½¥q§V¤O¦³¦¨
¼Æ¦~«eªLºaÀA¥ý¥Í´¿¨¥·sÃÄ¥¼¨Ó¸û¯àÁÈ¿ú¦³Àù¯gÃĤκ믫¯fÃÄ...©Ò¥H¤j®aÁͤ§Yõ¶R6575¦¹±m¨é
§ë¸ê·ÀI«ä¦Ò90%¥¢±ÑÂÔ·V¬°¤W...¨SÀò§Q§O¶R¦h¦]¬°¨SÀò§Q¬O¯u....·í§ë¸ê¾Ç²ß¦¨ªø
¬Û¹ï·Qªk¤£ÅÜ....Àò§Qªº¥Í§ÞÂåÀø«O°·¹«~ªÑ¨ÌµM¤@¤ù¤Ñ
¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-06-02
med.sina.com/article_detail_103_2_46664.html
¦pªG·í«e©Ò»{¬°ªºAD¥Dn¯f¦]³Ì²×³QÃÒ©ú¬O¤£¦¨¥ßªº¡A§ÚÌÁٯవ¨Ç¤°»ò¡H
1¡B§K¬Ì¯«¸g¾Ç
·í«e¡AÃö©óADµo¯f¾÷¨îªº¤@Ó¤é¯q¬y¦æªº°²»¡¬O¡A¸Ó¯f¹ê»Ú¤W¬O¥Ñ¤j¸£¤¤ªºª¢¯g©Î¯«¸gª¢¯g¤Þ°_ªº¡C
§¨Ó¯«¸g¬ì¾Ç°ª¯Å¥DºÞJennifer Lairdªí¥Ü¡A§K¬Ì¯«¸g¾Ç¬O§¨Ó«D±`·P¿³½ìªº¤@Ó»â°ì¡A¦ý¸Ó»â°ì¤´³B©ó«Ü¦ªº¶¥¬q¡C
2¡BªíÆ[¿ò¶Ç¾Ç
¦è¯Z¤ú¥Íª«§Þ³N¤½¥qOryzon Genomics¤w¸g±Ò°Ê¤F¼ÆÓÁ{§É¸ÕÅç¡A¥Î¤@ºØÃĪ«¦P®É¹v¦V2ºØªíÆ[¿ò¶Ç酶¡A³o¨Ç酶±±¨îµÛ»PAD¬ÛÃöªº¦hÓ°ò¦]¡C
¦b¬ü°ê¡A¦Ê°·©MRodin Therapeutics¤]¦b¶}®iÁ{§É«e¬ã¨s¡A½Õ¬d¥t¤@ºØªíÆ[¿ò¶Ç¾ÇÃĪ«¡A³oºØÃĪ«¹v¦V¯«¸g¬ðIJ¼u©Ê¡]synaptic resilience¡^¡A¤£¬OÃöª`©ó´î¤Ö¯«¸g¤¸ªº¥á¥¢¡A¦Ó¬O«OÅ@¯«¸g¤¸¤£¥¢¥h¥¦Ì¤§¶¡ªº¬ðIJ³s±µ¡C
3¡B·L¥Íª«²Õ¾Ç
·í«e¡A¤H̤é¯qÃöª`ªº¥t¤@Ó¬ã¨s»â°ì¬O·L¥Íª«²Õ¡]microbes¡^¡C¥Ø«e¤wª¾¡A¥Í¬¡¦b§Ú̸z¹D¤¤ªº·L¥Íª«²Õ¯à³q¹L©Ò¿×ªº¸z-¸£¶b¡]gut-brain axis¡^¼vÅT§Ú̪º¤j¸£¡A¥¦Ì¤w»Pºë¯«¯e¯f¡]¦p©¬ª÷´Ë¯f¡^¥H¤Î¯«¸g°h¦æ©Ê¯e¯f¡]¦pAD ¡^ÃöÁp°_¨Ó¡C
AD»P·s³¯¥NÁ¤§¶¡ªº½Ñ¦hÃöÁp¤¤¡A¬ã¨s³Ì¦hªº¤@ÓÃöÁp¬OÁx©T¾J¡C¾¨ºÞ¥Ø«eÁÙÃÒ¾Ú¤£¨¬¡A¦ý¦³¤@¨Ç¬ã¨s«ü¥X¡AÁx©T¾J¦b¤j¸£¤¤ªº¿n²Ö¥i¯à¥[³tADªº¶i®i¡C¥Ø«e¡A¤@®a¦W¬°Brain Vectisªºªk°ê¤½¥q¥¿¦b§Q¥Î³o¤@°²»¡§@¬°¶}µo¤@ºØ°ò¦]Àøªkªº°ò¦¡A¸Ó°ò¦]Àøªk¦®¦b¬@±Ï¤j¸£¤¤ªº¥¿±`Áx©T¾J¥NÁ¡AºÓ¤HÅéÁ{§É¸ÕÅç¹wp±N¦b2021¦~±Ò°Ê¡C
4¡B°ò¦]Àøªk
°ò¦]Àøªk¦³±æ¦¨¬°ªvÀøADªº¥t¤@ºØ¤â¬q¡C¾¨ºÞº§åÁ{§É¸ÕÅ礤¦³¤@Ó¤w¸g¥¢±Ñ;¦ý³oºØªvÀø¤èªk¤w³QÃÒ©ú¬O¦w¥þªº¡A¨Ã¥B@¨ü©Ê¨}¦n¡C¥¼¨Óªº¬ã¨s¡A¥i¯à±Ä¨ú°w¹ïAD¶i®i¦³¹ê½è©Ê¼vÅTªº¨ä¥L¹v¼Ð¶i¦æ´ú¸Õ¡C
**************************************************************************************
¦Ü©óf¥Ò»Ä¶uªº¥\¥Î¦³´XÓ?
liaw6575¤j¤j¼g¤F¨t¦Cªº±M¤å
liawbf.pixnet.net/blog/category/2056459
¨ä¤¤¦³Ãö¸z-¸£¶b¡]gut-brain axis¡^ªº¤j¤å
liawbf.pixnet.net/blog/post/47614899
ÁÙ¦³JOE COHEN ¥ý¥Íªº¥¬¬¥®æ
f¥Ò»Ä¶u¡]¹«~¨¾»G¾¯¡^ªº°·±d¯q³B
www.selfhacked.com/blog/sodium-benzoate-some-preservatives-block-inflammation-and-autoimmune-disease/
f¥Ò»Ä¶u¹ï°·±d¼vÅTªºÁ`µ²
f¥Ò»Ä¶u¡G
.³q¹L¼W¥[ªø®Éµ{¼W±j¡]LTP¡^©M¬ðIJ¥i¶ì©Ê¡]R¡^¼W¥[°O¾Ð¤O¨Ã¥B¬O»{ª¾¼W±j¾¯¡C¾÷¨î¬O³q¹LNMDA¿E¬¡¡]R¡^¡C
.³q¹LCREB¬¡¤Æ¡]R¡^¼W¥[¤j¸£¤¤ªº¥Íªø¦]¤l¡A¦p BDNF©M¯«¸gÀç¾i¦]¤l-3 ¡C
.¹³¤@¨Ç¥L¥ÅÃþÃĪ«¤@¼Ë°§CÁx©T¾J¡]R¡^
.f¥Ò»Ä¶u´î¤Öª¢¯g©MÁx©T¾J
.f¥Ò»Ä¶u©MD-®ò°ò»Ä®ñ¤Æ酶
.»{ª¾¼W±j
.f¥Ò»Ä¶u¦p¦ó°§C¦Û¨§K¬Ì©Mª¢¯g
.f¥Ò»Ä¶u¦p¦ó°§CÁx©T¾J©M°§Cª¢¯g
Immunomodulation of experimental allergic encephalomyelitis by cinnamon metabolite sodium benzoate
(¦×®Û¥NÁª«f¥Ò»Ä¶u¹ï¹êÅç©ÊÅܺA¤ÏÀ³©Ê¸£¯áÅ誢ªº§K¬Ì½Õ¸`§@¥Î)
Kalipada Pahan
www.ncbi.nlm.nih.gov/pmc/articles/PMC3206174/
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
¤£¥Î·Q¤Ó¦h°Õ...
¥i¥H¬Ý¤@¤U liaw6575¤j¤j¤µ¤é±M·~ªº·s§@ SNG-12 PK SAGE-217 ºë±m¤ÀªR..
¤å¤¤«ÂI SNG-12¤G´Á¸ÕÅ禳°µ¨ì6©Pªø´ÁªvÀø..SAGE-217¥u°µ¨ì2©P...
¦Ó¥BSNG-12¶VªøªvÀø,®ÄªG¶q¶V¤j,¥iªø´Á¨Ï¥Î...
¬O§_SAGE-217¥iªø´Á¨Ï¥Î?«½Æ¨Ï¥Î¦³µL¦w¥þºÃ¼{?¤´«Ý¬dÃÒ...
¶i«×¹ï¤ñ...SNG-12¶i«×¤W¥Ø«e¬O»·»·¶W«e..¤w®Öã¶i¤J¤T´Á...
¼~Æ{¯g¨C¦~116»õ¬üª÷¥H¤Wªº¥«³õ...´Á«Ý½²±Ð±Â¹Î¶¤¦¤é§¹¦¨·sÃĬãµo..Åý·sÃĤW¥«!
¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ~~
liawbf.pixnet.net/blog/post/47956260
ÁÂÁ±z´£¨Ñ·Qªk©M¼Æ¾Ú¤ä«ù
¦Û¤v¤@Ó¤HÁ`¬O·|·Q¤Ó¦h
³o®ÉÔ´N·|»Ýn¹Ù¦ñ¨Ó°í©w«H¤ß
§Ú¬O»{¬°´N¹³FDAµ¹¤¤¸ÎÁ{§É¤H¼ÆÀu´f¥H¤Î
¤ß®®SND12¦bÃøªv«¬ºë¯«¤Àµõ¯gª§¨ú¨ì©t¨àÃĸê®æ
¤@¼Ë
§Ú̳£¤£·|ª¾¹D±µ¤U¨ÓªºÁ{§ÉSAGE-217¬O§_·|¦]¬°BTD¸ê®æ©M¼Æ¾Ú¦Óª§¨ú¨ì¤°»ò
««×¼~Æ{¯gªºÁ{§É¤£ª`·N¡A¶i«×«Ü§Ö´N·|³Q°l¤Wªº¡A¤£¯à¤Ó¤j·N
·íSAGE-217ÀòBTDªº¦P®É ¤p§Ì¤]©M±z¦³¦P¼Ëªº·Qªk
¤£¹L¦b³s¦êªº«ä¦Ò«á ¬Ýªk¤w¦³©Ò§ïÅÜ ¦ý¤£ª¾¹ï¤£¹ï
SAGE-217 ·íµM¬O¤@Ó±j«lªº¹ï¤â
¦Ñ¥v¤j¤j¤]¤ÀªR¤ñ¸û¹LSAGE-217 ©M SNG-12ªºÃÄ®Ä
¸Û¦p±z©Ò´£ªº
¡§ SAGE-217¥i´£°ª¤F¯f±w¾ãÅéºÎ¯v®É¶¡¤ÎºÎ¯vºûÅ@85% (30mg ªº¥ÎÃÄ) »P 88% (45mg ªº¥ÎÃÄ)¡C¦w¼¢¾¯ªººÎ¯v¦³®Ä²v¤¤¦ì¼Æ´£¤É¤F 73%¡C¼Æ¦r®t¶Z¤£¤j . ¡§
¦w¼¢¾¯ªº®ÄªG«Ü°ª ©M¦Ñ¥v¤j¤jªº´£¥Ü¬Û¦P
¦AªÌ
SNG-12¤]¯à°§C¥¢¯v©M¯«¸gµJ¼{
HAMD-17ªº¥¢¯v / ¯«¸gµJ¼{¤À¼Æ¥§¡¥Ñ 6.6 ¤À°§C¨ì 3.07 ¤À
©M citalopram ¬Û¤ñ¹F0.01ÅãµÛ¤ô·Ç ®ÄªG¶q 0.99
½Ð°Ñliaw6575¤j¤jªº±M¤å liawbf.pixnet.net/blog/post/47559201
§Ú¤£ª¾¹D³o¦p¦ó¤ñ¸û±EÀu ?
¤TªÌ
SNG-12¦h¤F¤@¶µªvÀø¦Û±þ·N©À
Liaw6575¤j¤jªº¤j¤å ¡§ §Ü¼~Æ{SSRIÃĪ«´£°ª¦Û±þ²v? SNG-12ªº¾÷·| ¡¨
liawbf.pixnet.net/blog/post/47448768
¤j¤j¦a¼W¥[SNG-12ªºªþ¥[»ùÈ ? ©Î»P¥«³õ°µ¥X°Ï¹j ?
¥xÆW¥«³õµ¹¤ß®®ªºµû»ù ·|§_¤Ó¼ÖÆ[ ? §Ú¤£ª¾¹D
¦ý¤ñ¤§SAGE ¤W©P¤¦¬½LªºÁ`¥«È 72.225 »õ¬ü¤¸
¦P¼Ë¾Ö¦³¨âÓBTD
¤ß®®´X¥G¬O¤H®aªº§À¼Æ¦Ó¤w
¤p§ÌÆ[ÂI©Î¥¢¤§°¾»á
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
§A¶Kªº¨º½gSAGE-217¬O¤µ¦~2¤ëªº³ø¾É...¼g¨ì¬OSAGE-217¦b¹êÅçµo²{...
²{¦b¦pªG¦³¶i«×ªº¸Ü...SAGE-217³Ì¦hÀ³¸Ó¥u¦b1¦Ü2´Á§a...
¦ý..¥Ø«e¤ß®®¤w¸g³q¹L2´Á...FDA®Öã¶i¦æ¤T´ÁÁ{§É¤F...
·sÃĶi¤J¤T´ÁÁ{§É..¯f¤H¹ï¤ß®®3´Áªº·sÃÄ...¬Û¹ï«H¤ß«×·|¤ñ¸û°÷³á...
¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ
§Ú»{¬°nª`·NSAGE-217ªºÁ{§É¶i«×
§Ú·Q¦bÁ{§É¦¬®×¤W¤]¬O
SNG12¤T´Á©MSAGE-217¤Ó±µªñ¤]¤£¤Ó¦n
Á{§Én¬D¯f¤H¡A¯f¤H¤]¤@¼Ë¬On¬DÁ{§É°Ñ¥[ªº
¼~Æ{¯gÃĪ«·N¥~¹ï¥¢¯v±wªÌµo´§®ÄªG SageªÑ»ù«G²´
news.cnyes.com/news/id/4031396
³o½g·s»D¸Ì´£¨ì
SAGE-217¥i´£°ª¤F¯f±w¾ãÅéºÎ¯v®É¶¡¤ÎºÎ¯vºûÅ@
85% (30mg ªº¥ÎÃÄ) »P 88% (45mg ªº¥ÎÃÄ)¡C¦w¼¢¾¯ªººÎ¯v¦³®Ä²v¤¤¦ì¼Æ´£¤É¤F 73%¡C
¼Æ¦r®t¶Z¤£¤j¡AÁÙ¬Oȱo°lÂÜ«áÄòÁ{§É¹êÅç
¼~Æ{¯g±wªÌ ¤E¦¨·|¥¢¯v
news.ltn.com.tw/news/life/paper/247197
±q³o½g¤å¥i¥H¤F¸Ñ
¼~Æ{¯g±wªÌ¹ï©óºÎ¯v§ïµ½¦³¬Û·íªº»Ý¨D©Ê
ªø¤[¥H¨ÓÁ{§É¤]Ãҹ꦳¨Ç¦w¯vÃĬO·|¦¨Å}ªº¡A¦w¯vÃĪº¦¨Å}«ÜÃø³B²z¡A¤£¤ñ§Ù¬r®e©ö
·Pı¤W¹ï¯f±w¨Ó»¡SAGE-217¥iªvÀø¼~Æ{¯g¤S¯à§ïµ½¥¢¯v¡A¬O¤@ӫܦnªº¿ï¾Ü
ÁöµM¤Ï´_ªA¥ÎSAGE-217¤Îªø´Á©ÊªA¥Î¹ï©ó®ÄªGªº¼vÅTÁÙ¥¼³Q±´°Q
¦ý¤£¯à¤Ó´Á«Ý¹ï¤âªºªø´Á¦w¥þ©Ê¥X°ÝÃD
SNG12ªºÀø®Ä«ü¼Ð¬°¦Û±þ¯gª¬«Ü´Î¡A¹ï¯f±w¨Ó»¡ºÎ¯v«~½è¯à§ïµ½¤]¬O«Ü¦n
¥i¯à¥HÁ{§É¨Ó»¡·|«µø¦Û±þ¡A¥Í©R¬O³Ì«nªº
¤£¹L¤]¤£±Æ°£¯f±w¶¡¥i¯à·|¦]¬°ºÎ±o¦n©E¦n¹D¬Û报¡A¼W¥[©MÂå®v°Q½×§ïªA¥ÎSAGE-217ªº¥i¯à©Ê
¤£¯à¤Ó¼ÖÆ[
¤W¥«®É¶¡¤Ó¬Ûªñ§Ú·|¾á¤ß¬O±j¹ï±jµw¸Iµw¡A¦A¨Ón¤ñªº·|¬O±ÂÅv¹ï¶H°÷¤£°÷¦³¤O¤F
½²±Ð±Â¥Î¤FGrand regulator¨Ó§Î®e¡A³o·|¤£·|¬OCNS»â°ìªº Grand Slam?
Editorial (Thematic Issue: Regulating the CNS Grand Regulator; N-methyl-D-aspartate Receptor-Mediated Neurotransmission)
Author(s): Guochuan Emil Tsai.
Journal Name: Current Pharmaceutical Design
Volume 20 , Issue 32 , 2014
DOI : 10.2174/1381612820666140204121732
5/24 ¤ß®®µo¤FSNG-12 ªº¸É¥R¤½§i¡A¨ì©³¬O£¸Ó¤°»ò¼ËªºÂà§é¡H
¦n·Qª¾¹D§r¡I
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a¡I
¤]´Á«Ý¥¼¨Ó¤½¥q¦³±æ¥Ó½Ð²Ä3±iBTD...
--------------------------------------------------------------------------------
¥»¤½¥q«h¬O³z¹L¥ÌÓi»Ä§í¨î¦A¦^¦¬¾÷Âà(glycine transporter-1 inhibition)¡A¼W¥[
¬ðIJ¶¡ªº¥ÌÓi»Ä¿@«×¥H¬¡¤ÆNMDA¥\¯à¡A¦b¥ý´ÁÁ{§É¸ÕÅç¡A¹ï¼~Æ{¤Î¦Û±þ¯gª¬ªºªvÀø®Ä
ªG¬Ò§Ö©ó¡B³Ó©ó¿ï¾Ü©Ê¦å²M¯À¦A§l¦¬§í¨î¾¯ Citalopram¡A¨Ã¥B¦bÃĪ«¦w©w©Ê¤Î±M§Q
¦³¬ð¯}«á¡A¶i¤J¤T´ÁÁ{§É¸ÕÅç¡C
--------------------------------------------------------------------------------
´Á¬ß¤½¥q¥¼¨Ó¯àÂǥѴ£¨Ñ²{ªp¸ê°T...Åý¼s¤jªº§ë¸ê¤H¹ï¤ß®®ªº¬ãµo¦³§ó¦hªº»{ÃÑ...
¥H¤W~~·PÁÂ~~
§i¶D§ë¸ê¤j²³¼~Æ{¯gÃĪ«¥«³õ²{ªp , µ¹¤©©ç©ç¤â
§Æ±æ¤½¥q¥¼¨Ó¦h¦h»¡©ú , Åý§ë¸ê¥«³õ¹ï¤ß®®ªº¬ãµo¦³§ó¦hªº»{ÃÑ
ÁÂÁ½²±Ð±Â
¥t¥~,¤½§i¤¤ªº²Ä(5)¶µ
[(5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G±N®Ú¾Ú¥»´ÁÁ{§É¸ÕÅçµ²ªG¨M©w¬O§_»Ýn¶i¦æ¡C]
³o¦³¦ó·N²[¶Ü?
³o¬O»¡
¥Ø«e¦b¨S¦³BTDªº±¡ªp »Ý°µ¨âÓÁ{§É¤T´Áªº²Ä¤GÓ¶Ü?
§í©Î¬O
°µ§¹³oÓ¤T´Á ±NµøÃĮı¡ªp ¥Ó½ÐBTD? ¦]¬°¥Ø«e¦Û±þ¯gª¬¨ÃµLÃĪ«ªvÀø ¦Ó¿ï¾Ü³oÓ¬ð¯}¤f?
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
------------------------------------------------------------------
·PÁ¤½¥q²Ó¤ß´£¨Ñ¥h¦~³Ì·s¥«³õ²{ªp¬ù 116»õ¬ü¤¸...
-------------------------------------------------------------------
¥Ø«e¥h¦~¥«³õ´N¦³116»õ¬üª÷³á...50»õ¬üª÷¬O«ü2012¦~.¨º¦~½æ³Ì¦nªº§Ü¼~Æ{ÃĪ«...
¥Ø«e¼~Æ{¯gªº¥«³õ...¨Ì¤½¥q³Ì·s´£¨Ñªº¸ê®Æ...
¥h¦~2017¦~§Ü¼~Æ{ÃĪ«ªº¥«³õ..¤j¬ù116»õ¬üª÷...
¹w¦ô2018-2023¦~ªº¦~½Æ¦X¼Wªø²v¬ù1.8%¡C
------------------------------------------------------------------------------------------------------
®Ú¾Ú¥«³õ¬ã¨s¡A2017¦~¥þ²y§Ü¼~Æ{ÃĪ«(antidepressants)¤j¬ù116»õ¬üª÷¡A
¹w¦ô2018-2023¦~ªº¦~½Æ¦X¼Wªø²v¬ù1.8%¡C
------------------------------------------------------------------------------------------------------
¥»¤H5/23 µo¤åªº90»õ¬ü¤¸¥«³õ¸ê°T¬°2016¦~¬Ý¨ìªº¹w¦ô..
·PÁ¤½¥q²Ó¤ß´£¨Ñ¥h¦~³Ì·s¥«³õ²{ªp¬ù117»õ¬ü¤¸...
¥i¨£¼~Æ{¯gÃÄ«~¥«³õ¬O°ª¦¨ªø©Ê...¦ý³o¤]¥Nªí¯f¤H¤£Â_¼W¦h...
´Á¬ß¤½¥q¯à¦¤é®³¨ìÃÄÃÒ...±N§ó¦³®ÄªºªvÀø±À¼s¦Ü¥þ¥@¬É¦³»Ýnªº¯f¤H¡C
·P®¦!
¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸êªÌ°Ñ¦Ò...
(6575)¤ß®®-¤½§i¥»¤½¥q¬ãµo¤¤««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡AÀò±o¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)®Öã°õ¦æ¤HÅéÁ{§É²Ä¤T´Á¸ÕÅç(¸É¥R¤½§i)
1.¨Æ¹êµo¥Í¤é:107/05/24
2.¤½¥q¦WºÙ:¤ß®®¥ÍÂåªÑ¥÷¦³¤½¥q
3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q
4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î
5.µo¥Í½t¥Ñ:¥»¤½¥q¬ãµo¤¤««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡AÀò±o¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)®Öã°õ¦æ¤HÅéÁ{§É²Ä¤T´Á¸ÕÅç¡C
(1)¬ãµo·sÃĦWºÙ©Î¥N¸¹:SNG12¡C
(2)¥Î³~¡G¼~Æ{¤Î¦Û±þ¯gª¬¡C
(3)¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¤T´Á¤HÅéÁ{§É¸ÕÅç¡C
(4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G
A.´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã¡G««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡AÀò±o¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)®Öã°õ¦æ¤HÅéÁ{§É²Ä¤T´Á¸ÕÅç¡C
B.¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G±N¨Ì¸ÕÅçpµe¶i¦æÁ{§É¸ÕÅç¡C
C.¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G·s¥x¹ô43,303¥a¤¸¡C
(5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G±N®Ú¾Ú¥»´ÁÁ{§É¸ÕÅçµ²ªG¨M©w¬O§_»Ýn¶i¦æ¡C
A.¹wp§¹¦¨®É¶¡¡G¹ê»Ú®Éµ{±N¨Ì°õ¦æ¶i«×¨M©w¡C
B.¹wpÀ³t¾á¤§¸q°È¡GµL¡C
(6)¥«³õ²{ªp:««×¼~Æ{(Major depressive disorder)¬O«Ü±`¨£ªººë¯«¯e¯f¡A¨CÓ¤H²×¨ä¤@¥Í¬ù
¦³15%ªº¥i¯à©Ê¿©±w¦¹¯e¯f¡A¥þ²y«Æ{±wªÌ¤j¬ù¤T»õ¤H¡C¾¨ºÞ³o¬O«Ü±`¨£ªººë¯«¯e¯f¡A¥B±w¯f²v±N¦]¦U¦¡¥Í¬¡ªÀ·|ÅܾE©Ò²£¥ÍªºÀ£¤O¦Ó³vº¥¤É°ª¡A¦ýÃĪ«¥«³õªº¦¨ªø²v«o¥¼¨£Ãzµo¡A¥Dnì¦]¦b©ó¡uÃĮĦ³¡v(Ãø¥H©M¦w¼¢¾¯°Ï¤À)¡B¡u¥¼¦³·s¾÷Âà·sÃÄ¡v¡B¡u¾Ç¦WÃÄ¥R¥¸¡vµ¥¡C®Ú¾Ú¥«³õ¬ã¨s¡A2017¦~¥þ²y§Ü¼~Æ{ÃĪ«(antidepressants)¤j¬ù116»õ¬üª÷¡A¹w¦ô2018-2023¦~ªº¦~½Æ¦X¼Wªø²v¬ù1.8%¡C
²{¦³§Ü¼~Æ{¾¯ÃĪ«³£°ò©ó³æÓi°²»¡¡C1950¦~¥N³æÓi®ñ¤Æ»Ã¯À§í¨î¾¯(monoamine oxidase inhibitors)¡B¤TÀô§Ü¼~Æ{ÃÄ(tricyclic antidepressants)¥ý«á°Ý¥@¡AµM¦¹¤GÃþÃĪ«°Æ§@¥Î¸û°ª¡A¥B«D±M¤@©Êªº§í¨î¯«¸g¶Ç¾Éª«½è¦A¦^¦¬¡F1980¦~¥N²Ä¤G¥N§Ü¼~Æ{ÃĪ«½Ï¥Í¡A°Æ§@¥Î¸û§C¥B§í¨î¯«¸g¶Ç¾Éª«½è¦A¦^¦¬ªº±M¤@©Ê°ª¡A¥i¥H¼W¥[¬ðIJ¶¡¯S©w¯«¸g¶Ç¾Éª«½èªº¿@«×¡AºÙ¬°¿ï¾Ü©Ê¦å²M¯À¦A§l¦¬§í¨î¾¯(selective serotonin reuptake inhibitors¡FSSRIs)¡A§¨Ó¤½¥qªºFluoxetine(°Ó«~¦W¡G¦Ê¼~¸ÑProzac)¡B¸¯Äõ¯ÀªºParoxetine (°Ó«~¦W¡G§J¼~ªGSeroxat) ¬O¸Ó®É
´Áªº¥NªíÃĪ«¡C¦Ê¼~¸Ñ±M§Q«OÅ@©ó2001¦~¨ì´Á«á¡A§¨Ó¤½¥qDuloxetine(°Ó«~¦W¡G¤d¼~¸ÑCymbalta) ©ó¬J¦³¦å²M¯À¾÷Âà¤W¦A¥[¤J§í¨î¥¿µÇ¤W¸¢¯À¦A¦^¦¬(serotonin-norepinephrine reuptake inhibitor¡FSNRIsÃþÃĪ«)¡A2012¦~³Ð³y¹O50»õ¬üª÷ªº¾P°âª÷ÃB¡C«áÄòÃĪ«¦h¦b³æÓi¾÷Âà¶i¦æ§ï¨}¡A¦pBupropionÄÝ©ó§í¨î¥¿µÇ¤W¸¢¯À¡B¦h¤ÚÓi¦A¦^¦¬¡C
¦Û¦Ê¼~¸Ñ°Ý¥@«á¡A¥þ²y§Ü¼~Æ{¥«³õÀò±o§Ö³t¶i®i¡AµM´N¦¹¤G¤Q¦h¦~ªº¥ÎÃĸgÅçµo²{¡AµL½×¬OSSRIs©ÎSNRIsÃþÃĪ«¡A¤j·§¥u¹ï35%ªº¯f±w²£¥Í®Ä¥Î¡A¦Ó¥B©¹©¹»ÝªAÃļƶg«á¤~·|³vº¥¦³ÃĪ«§@¥Î¡AµLªk¹ïºò«æªº¦Û±þª¬ªp¦³©ÒÀ°§U¡A«Ü¦h®ÉԬƦܵLªk©M¦w¼¢¾¯®Ä¥Î°Ï§O¶}¨Ó¡A³o¨Ç¯ÊÂI©úÅãµLªkº¡¨¬¼s¤jªº±wªÌ©Ò»Ý¡C³·¤W¥[Á÷ªº¬O¡A2004¦~¬ü°ê¹«~ÃĪ«ºÞ²z§½µo¥¬§Ü¼~Æ{ÃĪ«ªº²Î¤@ĵ¥Ü(black box warning)¡A »{¬°25·³¥H¤U¦~»´±Ú¸s¨Ï¥Î§Ü¼~Æ{ÃĪ«¦³¼W¥[¦Û±þ·N©Àªº·ÀI¡C¬O¬G¾Ç¬É¡BÃĬɫùÄò´M¨D³æÓi¥H¥~ªº·sªvÀø¾÷Âà¡A§Æ±æ¯à¶}µo¥XÃĮħó¦n¡B§@¥Î®É¶¡§óµu¡B°Æ§@¥Î§ó§C¡A¬Æ¦Ü¥i¥H°§C¦Û±þ·N©Àªº·s¾÷ÂàÃĪ«¡C¥Ø«e¬ONMDAªº½Õ±±¤Þ»â·¼é¡A¦pAllerganªºRapastinel¬ONMDA³¡¤À«ú§Ü¾¯¡A J&JªºEsketamine¬ONMDA«ú§Ü¾÷¨î¥H§Ö³t°§C¦Û±þ·N©À(¦ý¬O¦³Ãþ¦ü¨Ï¥ÎK¥L©Rªº·ÀI)¡C¥t¥~¦³Sage Therapeutics±Ä¥ÎGABA¥¿¦V²§¦ì½Õ±±¡C
¥»¤½¥q«h¬O³z¹L¥ÌÓi»Ä§í¨î¦A¦^¦¬¾÷Âà(glycine transporter-1 inhibition)¡A¼W¥[¬ðIJ¶¡ªº¥ÌÓi»Ä¿@«×¥H¬¡¤ÆNMDA¥\¯à¡A¦b¥ý´ÁÁ{§É¸ÕÅç¡A¹ï¼~Æ{¤Î¦Û±þ¯gª¬ªºªvÀø®ÄªG¬Ò§Ö©ó¡B³Ó©ó¿ï¾Ü©Ê¦å²M¯À¦A§l¦¬§í¨î¾¯ Citalopram¡A¨Ã¥B¦bÃĪ«¦w©w©Ê¤Î±M§Q¦³¬ð¯}«á¡A¶i¤J¤T´ÁÁ{§É¸ÕÅç¡C
6.¦]À³±¹¬I:µL¡C
7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:
(1)««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡A¹wp©MÃøªv«¬««×¼~Æ{¯g(SNA1)¤@¨Ö±Ò°Ê¦¬®×¡C
(2)SNG12 ì®ÆÃĬ°¥Ò°ò¥Ì®ò»Ä¦@´¹¡A¬O¥Ì®ò»Ä¦^¦¬§í¨î¾÷¨îªº·s¾÷Âà·sÃÄ¡A¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)½T»{¬°¡u·s¤Æ¾Ç¤À¤l¡v¡]New Chemical Entity¡^¨Ã¤wÀò±o¬ü°ê±M§Q¡C¤T´Á¸ÕÅ禳¨â¤jÁ{§É®Ä¥Î«ü¼Ð¡G¤@¬°¼~Æ{¯gª¬¥t¤@¬°¦Û±þ¯gª¬¡A¥Ø«e¦Û±þ¯gª¬¨ÃµLÃĪ«ªvÀø¡C¥H¥xÆW¬°¨Ò¡A¨C¤Ñ¬ù¤Q¤H¦Û±þ¨¤`¡A¨ä¤¤µ´¤j³¡¤À¿©¦³««×¼~Æ{¯g¡C
(3)·sÃĶ}µo¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥§ë¸ê·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_¡C
50»õ¬üª÷ªº¥«³õ!!
±z¯uªº·Q¤Ó¦h¤F..¿³ÂdªÑ²¼¬O¥H·í¤é§¡»ù§@¬°¹j¤é¶}½L»ù..¹sªÑ®Ú¥»¼vÅT¤£¤FªÑ»ù...
§Ṳ́£·|¦]¬°·í¤éªº¹sªÑ¶R©Î½æªº»ù®æ¦Ó¦³«ùªÑ¤Wªºªi°Ê...
¤ß®®ª©¤W·|¶Rªº¥H±M·~¤á.¤¤¹ê¤á©M¤j¤á§ë¸êªÌ..¥Hªø½u§ë¸êªÌ©~¦h...
¬Ýªº¬O¤½¥qªºÆF»î¤Hª«/¤½¥q·sÃĪº¥«³õ/¤½¥q·sÃĪº¦¨¥\²v...
§Ú̬ݪº¬O¤½¥qªº¥¼¨Ó©Ê...
¤j®aªºµo¤å..¬O¥H¤½¥q·sÃĬÛÃö¸ê°T°Q½×¬°¥D...
¥H¤W~~¨Ñµ½¨}.´¼¼zªº¾Ô¤Ḭ́ѦÒ~~
««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡A¹wp©MÃøªv«¬««×¼~Æ{¯g(SNA1)¤@¨Ö±Ò°Ê¦¬®×
¨º¬O§_2016 FDA®Ö㪺ADÁ{§É¸ÕÅç SND-14 , ¤]±N©M SND-51 ¤@¨Ö±Ò°Ê¦¬®× ?
¿D¬w¾ÇªÌªº¬ã¨s
Molecular Targets of Tannic Acid in Alzheimer¡¦s Disease.
www.ncbi.nlm.nih.gov/pubmed/28176625
Abstract
Tannic acid (TA)has strong antioxidant/free radical scavenging, antiinflammatory, anti-viral/bacterial, and anti-carcinogenic properties.
TA¨ã¦³±j§Ü®ñ¤Æ¾¯/¦Û¥Ñ°ò²M°£¡A§Üª¢¡A§Ü¯f¬r/²Óµß©M§ÜPÀù©Ê
The neuroprotective effects of TA against AD have been shown in several in vitro and in vivo models of AD.
Apart from its potent antioxidant and anti-inflammatory roles, evidence suggests that TA is also a natural inhibitor of £]-secretase (BACE1) activity and protein expression.
BACE1 is the primary enzyme responsible for the production and deposition of A£] peptide.
TA also destabilises neurotoxic amyloid beta (A£]) fibrils in vitro.
Apart from its effects on the A£] cascade, TA can also inhibit the in vitro aggregation of tau peptide, a core component of intracellular neurofibrillary tangles (NFTs).
This review summarizes the relevance of TA and TA-related vegetable extracts (tannins) in the pathogenesis of AD and its enzymatic targets.
It also highlights the significance of TA as an important lead compound against AD.
¥t¥~, SNG-12 ª½§ð¤T´Á ©Î³\¤]¥NªíµÛ¤½¥qªº«H¤ß( ? or ! )
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
³o°ÝÃD..±M·~ªº¦Ñ¥v¤j¤j©ó2¤ë¥÷¦³Á|¨Ò»¡©ú¦p¤U...°µ¤F¤T´Á¤~¥h¥Ó½ÐBTD¬O¥i¥Hªº
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2018/2/6 ¤U¤È 11:05:44²Ä 286 ½g¦^À³
¤@¯ë»¡¨Ó¡AFDA§Æ±æ¥Ó½ÐBTDªº®É¶¡¤£n±ß©óEOP2¡AèèZogenix«Å¥¬¥LÌ®aªº§C¾¯¶q´îªÎÃÄÀò±oDravet SyndromeªºBTD¡A®Ú¾Úªº«o¬O¤T´ÁÁ{§Éµ²ªG¡¨ the results from Study 1, Zogenix¡¦s first global Phase 3 trial of ZX008¡¨¡A¤]´N¬O»¡°µ¤F¤T´Á¤~¥h¥Ó½ÐBTD¬O¥i¥Hªº¡A·s»D½Z³sµ²¦p¤U
zogenixinc.gcs-web.com/news-releases/news-release-details/zogenix-announces-receipt-fda-breakthrough-therapy-designation¡A
³oÓÁ{§É¼Æ¾Ú³y¦¨¥h¦~9/29³æ¤é¼Éº¦172%¡A¥«È½Ä¤W12»õ¬üª÷¡A¥ú¨~¤@«×À£¹LGW¡C
§Ú¤£À´n©È¤°»ò¡H¥i§_¶}ÄÀ¤@¤U
º¥ý¿³Âd¶}½L»ùªººâªk¬O«e¤@¤é¦¨¥æ§¡»ù¡A¤]´N¬O»¡¥Î1ªÑ10ªÑ©Ô¦A°ª¡A²Ä¤G¤Ñ§¡»ù´N¥´¦^ì§Î
¦A¨Ó¿³Âd¬O¤H¤u·b¦X¡A²{»ù¦Aº}«G¹ê»Ú¦¨¥æ´N¬O¤£¤@¼Ë¡A¨S¦³¹ê»Ú¶R½Lªº¸Ü¡A³oºØ1ªÑ10ªÑ¬O¶R¤£¤W¥hªº
¤Ï¥¿n¶R, ¦³®ÉÔ¶R¤@¨â±i, ¦³®ÉÔ¶R1ªÑ, ¦³®ÉÔ¶R10ªÑ,100ªÑ
³o´N¹³¹sªÑ¥æ©ö...¤j¤j¤£¥ÎÅå³Y¤Ó¦h¤~¬O...
¸Ü»¡SNG 12¬ðµMÃz½Ä¨ìÁ{§É¤T´Á, ³o¥Nªí¬Æ»ò?
¾÷Âà³QFDA±j¯P»{¥i? ÂåÀø¥¼³Qº¡¨¬ªº¯f¼x³QFDA±j¤O±ÀÂË? ³]p¨}¦nªºP3Á{§É´ú¸Õ ?
¯uªº¬Oªí¥Ü¤ß®®¦³»{¯u¦b°µ¨Æ.
¤£¦Ppipeline¤@ª½¦b³W¹º¤¤ ·Pı¦h±m¦h«º¤F°_¨Ó...
®Ú¾Ú¥xÆW¸gÀÙ¬ã¨s°|¥Íª«¬ì§Þ²£·~¬ã¨s¤¤¤ßªº±À¦ô¡A
2015 ¦~¥þ²y§Ü¼~Æ{²£«~¥«³õ³W¼Ò¬° 87 »õ¬ü¤¸¡A
2020 ¦~±N¹F 93 »õ¬ü¤¸¡A
2015 ¦~∼2020 ¦~ªº¦~½Æ¦X¦¨ªø²v (CAGR) ¬° 1.25¢H¡C
¨º»ò¤ß®®ªº¦X²zNPV¬O¦h¤Ö...ª©¤W¦p¦³§ë¬ã³¡ªº¤j¤j...¥i®Öºâ¤@¤U...
¦b»ùÈ»·»·§C¦ô®É...»°§Ö¶R¶iªø´Á«ù¦³§a...
¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ
~n¾Ç²ß«e½ú!
Åý¤l¼u¸¤@·|!
¤£«æµÛ¥X³õ!³£µ¥¨º»ò¤[¤F~
¥»¤½¥q¬ãµo¤¤««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡A Àò±o¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)®Öã°õ¦æ¤HÅéÁ{§É²Ä¤T´Á¸ÕÅç
ÁÂÁ¤@°_¤À¨É¤µ¦~·sÃĬì§Þ¦~·|ªº¸ê°T....
§Ú̬ݨì..
½²±Ð±ÂºaÀò¥»¦~«×·sÃĬì§Þ¦~CNS»â°ìªº¥D«ù¤H...
³ø§i¦w±Æ«e¬q..²Ä¤G³õ...
¥DÃD:Facilitating NMDA System Balance to Address CNS Disorders
¥ú¬Ý³ø§i¥DÃD...«P¶iNMDA¨t²Î¥¿Å¸Ñ¨MCNS¯e¯f...¤µ¦~«×ªº³ø§iºë±m¥i´Á...
¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Ḭ́ѦÒ~~
¤p©¯¹B¤j¤¶²Ðªº
BIT¡¦s 16th Annual Congress of International Drug Discovery Science and Technology-2018
Theme: Rethinking the Next Big Things in Pharma Innovations
Time: August 16-19, 2018
Place: Boston Marriott Cambridge, USA
www.iddst.com/iddst2018/ScientificProgram3_5.asp
¨ä¤¤ CNS »â°ì
Session 3704: CNS and Neurodegenerative Disorders Drugs and Therapies
Day 3: Afternoon, Saturday, August 18, 2018
13:30-16:20
Chair: Dr. Guochuan E Tsai, CEO, SyneuRx Neuroscience; Professor-in-Residence, David Geffen School of Medicine, University of California at Los Angeles, USA
½²±Ð±ÂÁ¿ÃD
14:00-14:25
Title:
Facilitating NMDA System Balance to Address CNS Disorders
Dr. Guochuan E Tsai, CEO, SyneuRx Neuroscience; Professor-in-Residence, David Geffen School of Medicine, University of California at Los Angeles, USA
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
¤p©¯¹B¤j
bio man ¤j
booli ¤j
ªº¤À¨É
«Xù´µºë¯«¯f¾Ç®aVitaly Leonidovich MinutkoÂå¾Ç³Õ¤h...
(ºë¯«¯f¾Ç¤u§@¸gÅç¶W¹L35¦~.µÛ¦³7¥»¸Ô²Óªº±MµÛ.«X°êª¾¦Wªººë¯«¬ì¾Ç±M®a)
Vitaly Leonidovich¦b©P¤@14/05/2018 - 22:20¤À¨ÉªºªvÀøºë¯«¤Àµõ¯gªº·s¤èªk¤å³¹¤¤...
¤å¤¤´£¨ì¤j¦h¼Æ·sªº§Üºë¯«¯fÃĪ«±N©ó2019¦~¤W¥«¡C
¤å³¹³Ì«á¤]´£¨ìNaBen¡]f¥Ò»Ä¶u¡ASyneuRx°ê»Ú[¥xÆW]¤½¥q¡^¬OD-®ò°ò»Ä®ñ¤Æ酶ªº§í»s¾¯¡A
¨Ã¥B³Q´£Ä³¥Î©óªvÀøºë¯«¤Àµõ¯g¡C
°Ñ¦Ò¨Ó·½ºô§}minutkoclinic.com/blog-doktora-minutko
¥Ø«e¤w¤½¥¬20¦ì°ê»Ú·sÃĦ~·|ªº³ø§i¤H...
¤ß®® Dr. Guochuan E Tsai, CEO, SyneuRx Neuroscience¤w©ó³ø§i¤H¤§¤¤...
¥ú¬Ý·sÃĦ~«×³Ì«n·|ijÁܽЪº³ø§i¤H...¦U¦U¨ÓÀY¤£¤p...
¤ß®®½²±Ð±Â¦C©óº§å·sÃÄ·|ijªº³ø§iªÌ¤¤...³o·N¸q¬O¤°»ò?¤j®a¥i¥H¦n¦n·Q·Q~~
时间¡G2018/08/16-2018/08/18
¦a点¡G剑桥ªi¤h顿ÉE»¨°s©±
¦a区¡G ¬ü国
¥D办单¦ì¡G¦Ê奥®õ国际会议¶°团
¤@¡B会议°ò¥»«H®§
1¡B²Ä¤Q¤»届国际·s药发©ú¬ì§Þ¦~会
2¡B时间¡G2018¦~8¤ë16-18¤é
3¡B¦a点¡G剑桥ªi¤h顿ÉE»¨°s©±
4¡B规¼Ò¡G500+参会规¼Ò
5¡B语¨¥¡G^¤å
6¡B参ÉO¤è¦¡¡Gºt讲¡B参会¡B参®i¡B赞§U¡B¦X§@
7¡BÊI§}¡Gwww.iddst.com/IDDST2018/cn
¤G¡B¤j会¤¶绍
¥Ñª¾¦W国际会议¤½¥q¦Ê奥®õ国际会议¶°团¥D办ªº²Ä¤Q¤»届国际·s药发©ú¬ì§Þ¦~会¡]IDDST-2018¡^将¤_2018¦~8¤ë16-18¤é¦b¬ü国ªi¤h顿¥l开¡C
国际·s药发©ú¬ì§Þ¦~会2003¦~¥Ñ¦Ê奥®õ国际会议¶°团发°_¡AP¤O¤_为¥þ²y药ª«¬ã发领°ìªº¬ì学®a©M¥ø业®a·f«Ø¤@个¬Û¤¬¥æ¬yÉO¦X§@ªº国际¥¥x¡A为¦æ业发®i´£¨Ñ·s«ä¸ô¡B«ü¤Þ·s¤è¦V¡A¥H¦¹±À动¥þ²y药ª«¬ã发ªº进®i¡C国际·s药发©ú¬ì§Þ¦~会¤w经¦b¥_¨Ê¡B«n¨Ê¡B²`¦`¡B¤j¨Áµ¥¦a¦¨¥\举办¤F¤Q¤届¡A¦¨¥\¦a§l¤Þ¤F¹OÉE¦W¥@¬ÉµÛ¦W专®a¡B学ªÌ¡B¥@¬É500üL¨î药¥ø业°ªºÞ¡B创·s«¬¨î药¥ø业®a参ÉO¡A¬O·s药¬ã发领°ì«nªº«~µP©Ê会议¡C
¥»届¦~会¦@设¸m¤F26场专业§Þ术论坛¡A¥Dn¥]¬A¡G药ª«¬ã发ªº³Ì·s进®i¡A¥Î¤_药ª«¬ã发ªº³Ì·s§Þ术¡A药²z¤ô¥¤Wªº药ª«发现¡A计ºâÉó辅§Uªº药ª«发现¡A¹v¦V药ª«¡A·s«¬¤p¤À¤l§í¨î剂©M¿E动剂¡A¥Íª«ªv疗领°ì·s进®i¡A药ª«递°eªº¬ì学ÉO§Þ术¡A针对¥Dn¯e¯fªº药ª«¬ã发·s进®iµ¥¡C¦¹¥~¡A还将举办¤¤¬ü¥ø业®a°ª®p论坛¡A¥Íª«医药°ªºÝ¤H¤~©M项¥Ø对±µ会¡Bû\区©Û°Ó±À¤¶会¡B¤H¤~©Û¸u会¡Bªi¤h顿¥Íª«医药产业û\区¤Îª¾¦WÉóÌۦҹ°Ó务¬¡动¡C
¥»届¦~会将ÁÜ请¥@¬É500üL¨î药¥ø业°ªºÞ¡B国际µÛ¦W专®a学ªÌ¡B¬ü国国内¬Û关ÉóÌÛ¥Nªí¡Bª¾¦W¥ø业®aµ¥领衔¥D讲¡A¦@计200个报§i¡C将ÁÜ请来¦Û¥@¬É40¦h个国®a©M¦a区ªº¤W¤d¦ì药ª«¬ã发领°ìªº¬Û关专业¤H¤h参¥[会议¡A50®aµÛ¦W¥ø业参¥[®i览¡A将¦V¥@¬É®i¥Ü«¤j·s药创¨îªº«eªu§Þ术©M¬ì§Þ¦¨ªG¡A¤Þ导国际·s药¬ã发领°ìªº发®i趋势©M«eªu动¦V¡A«P进¬ì¬ã¦¨ªG产业¤Æ¦X§@¡C
§Ú们诚挚¦aÁÜ请¬Û关领°ìªº专®a学ªÌ©M¥ø业¥Nªí参会参®i¡AÉO国内¥~¦P¦æ¬Û¤¬学习¥æ¬y¡B¦@¦P¦X§@¡I
¤T¡B¥Dn¬¡动
1. ²Ä¤Q¤»届国际·s药发©ú¬ì§Þ¦~会¤j会开¹õ¦¡º[¥þÊ^论坛
2. ªñ30场¥¦æªº¬ì§Þ论坛
3. ¦æ业专®a欢ªï±ß®bÉO艺术ªíºt
4. ²Ä¤Q¤»届国际·s药发©ú¬ì§Þ¦~会¤j会闭¹õ¦¡
5. ¥þ¥@¬ÉµÛ¦Wªº¥Íª«医药°ò¦aªi¤h顿¤@¤é´å
6. ¥ø业ÉO学术®ü报®i¥Ü
7. ¨î药产«~¡B§Þ术¡BªA务¥ø业®i览¬¢谈
¥|¡B³¡¤À报§i¤H¡]±Æ¦W¤£¤À¥ý¦Z¡^
Dr. Mostafa A El-S
¦p¬Q¤é±z´£¨ìªº¨£¸Ñ..+1...
<<¬O¶¥¹ï©Ê¥ô°È§¹¦¨ , Âà¥ô°ê»Úµ¦²¤µo®iÅU°Ý , ±N¦ì¤lÅýµ¹¤½¥q¤U¶¥¬qµo®i¥D¶bªº±M·~¤H¤~?
¥B¤U¤@Ó¬£¥ôSyneuRx International Corp.ªºªk¤H¸³¨Æ¥Nªí¤H , ·|¤]¬O¤ß®®ªº°õ¦æ°ÆÁ`¶Ü? >>
¤½§i¥»¤½¥qªk¤H¸³¨Æ¥Nªí¤H§ï¬£¤Î²Öp¤T¤À¤@¥H¤W¸³¨Æµo¥ÍÅÜ°Ê
1.µo¥ÍÅܰʤé´Á:107/05/10
2.ªk¤H¦WºÙ:SyneuRx International Corp.
3.ÂÂ¥ôªÌ©m¦W¤Î²¾ú:SyneuRx International Corp. ¥Nªí¤H:§d¶®¬Â³Õ¤h¡A
¥»¤½¥q°õ¦æ°ÆÁ`
4.·s¥ôªÌ©m¦W¤Î²¾ú:SyneuRx International Corp. ¥Nªí¤H:¤ý´º¥¿¡A
¥»¤½¥q¬ãµo³¡°ÆÁ`
5.²§°Êì¦]:ªk¤H¸³¨Æ§ï¬£¥Nªí¤H
6.ì¥ô´Á¡]¨Òxx/xx/xx ~ xx/xx/xx¡^:105/06/27~108/06/26
7.·s¥ô¥Í®Ä¤é´Á:107/05/10~108/06/26
8.¨ä¥LÀ³±Ô©ú¨Æ¶µ:¦P¥ô´Á¸³¨ÆÅܰʤñ²v:7/9
¤½§i¥»¤½¥qªk¤H¸³¨Æ¥Nªí¤Hº[°õ¦æ°ÆÁ`Ãã¥ô¤Î²Öp¤T¤À¤@¥H¤W¸³¨Æµo¥ÍÅÜ°Ê
1.µo¥ÍÅܰʤé´Á:107/05/09
2.ªk¤H¦WºÙ:SyneuRx International Corp.
3.ÂÂ¥ôªÌ©m¦W¤Î²¾ú:SyneuRx International Corp. ¥Nªí¤H:§d¶®¬Â³Õ¤h¡A
¥»¤½¥q°õ¦æ°ÆÁ`
4.·s¥ôªÌ©m¦W¤Î²¾ú:¤£¾A¥Î
5.²§°Êì¦]:ªk¤H¸³¨Æ¥Nªí¤Hº[°õ¦æ°ÆÁ`Ãã¥ô¡AÂà¥ô°ê»Úµ¦²¤µo®iÅU°Ý
6.ì¥ô´Á¡]¨Òxx/xx/xx ~ xx/xx/xx¡^:105/06/27~108/06/26
7.·s¥ô¥Í®Ä¤é´Á:NA
8.¨ä¥LÀ³±Ô©ú¨Æ¶µ:¦P¥ô´Á¸³¨ÆÅܰʤñ²v:7/9
½²±Ð±Âªº¤Ò¤H§d¶®¬Â³Õ¤h Ãã¥ôSyneuRx International Corp.ªk¤H¸³¨Æ¥Nªí¤H
º[¤ß®®°õ¦æ°ÆÁ`
³o¬O¦n®ø®§? ÁÙ¬OÃa®ø®§?
¬O¶¥¹ï©Ê¥ô°È§¹¦¨ , Âà¥ô°ê»Úµ¦²¤µo®iÅU°Ý , ±N¦ì¤lÅýµ¹¤½¥q¤U¶¥¬qµo®i¥D¶bªº±M·~¤H¤~?
¥B¤U¤@Ó¬£¥ôSyneuRx International Corp.ªºªk¤H¸³¨Æ¥Nªí¤H , ·|¤]¬O¤ß®®ªº°õ¦æ°ÆÁ`¶Ü?
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!
¨Ó·½¡G ¦Ì¤ººô ¡@2018-05-08
med.sina.com/article_detail_100_1_45426.html
2018¦~5¤ë7¤é¡Aºñ¸»sÃÄ(2186.HK)»PAstraZenecaq¥ß¸ê²£¦¬Áʤγ\¥i¨óij¡A«ü©w¦a°Ï³\¥i¸ê²£³\¥iÃÒÂл\51Ó°ê®a©M¦a°Ï¡A¥]¬A¤¤°ê¡B^°ê¡B¤Ú¦è¡B¿D¤j§Q¨È¡B¨F¯Sªü©Ô§B¡B¾¥¦èô¡B«nÁú¡B®õ°ê¡Bªü®Ú§Ê¡B°¨¨Ó¦è¨È¤Î¨ä¥L¦ì©ó¨È¬w¡B©Ô¤B¬ü¬w¡B«D¬w¡B¤j¬v¬w©MªF¼Úªº°ê®a©M¦a°Ï¡CÂàÅý¸ê²£¤Î³\¥i¸ê²£¦¬ÁÊ»ù¤§Á`ª÷ÃB¬°546¦Ê¸U¬ü¤¸¡C
²£«~¸ê®Æ
«ä·ç±d(´I°¨»Ä喹²¸¥¡B³tÄÀ¡BIR)¤Î«ä·ç±d½wÄÀ¤ù(½wÄÀ»s¾¯)¤D¨ã¦³§Ü§íÆ{¯S©Êªº«D¨å«¬§Üºë¯«¯f(AAP)ÃĪ«¡C
«ä·ç±dªº¥Dn¯f¯g¬OªvÀøºë¯«¤Àµõ¯g©MļÆ{¯g¡C«ä·ç±d½wÄÀ¤ù¦bY¤z¥«³õ¥çÀòã¥Î©ó§íÆ{¯g©M¼sªx©ÊµJ¼{¯g¡C
ºñ¸»sÃĪí¥Ü¡A¥Ø«e¤j¶q±wªÌ¤Î¼ç¦b±wªÌ¦³¹ïºë¯«¤Àµõ©MļÆ{¯gªvÀø²£«~ªº»Ý¨D¡A±N¬°¶°¹Î§e²{«¤jªº¥«³õ¾÷¹J¡C
¥~¸ê4¤ë¥÷¶R¤J¤ß®®¦@31±i...¥~¸ê¼W¥[¿³Âdªº«ùªÑ...ȱoª`·N...
¨Ó·½ : ¦U¦~°]³ø
104¤W¥b¦~ : 36,544
104¤U¥b¦~ : 47,693
105¤W¥b¦~ : 56,337
105¤U¥b¦~ : 68,172
106¤W¥b¦~ : 94,128
106¤U¥b¦~ : 168,063
¶È¨Ñ°Ñ¦Ò
ÁÂÁ¤j®a!